A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations

Morton W. Miller, E. Carr Everbach, C. Cox, Ryan R. Knapp, Andrew A. Brayman, Teresa A. Sherman

Research output: Contribution to journalArticlepeer-review

Abstract

This project tested the hypothesis that a 'second-generation' ultrasound (US) contrast agent (Optison™), offering extended echogenicity over that of its 'first-generation' predecessor (Albunex®), would have the greater potential for sonolysis of human erythrocytes in vitro. Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed in vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (∼2.8 to 0.38 MPa P-) regimens; pulse duration (200 μs) and interpulse interval (20 ms) were held constant. The data supported the hypothesis, with an overall ratio of ∼2.5 for relative extent of background-corrected US-induced hemolysis of the Optison™/Albunex® regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis.

Original languageEnglish (US)
Pages (from-to)709-721
Number of pages13
JournalUltrasound in Medicine and Biology
Volume27
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Albunex®
  • Hemolysis in vitro
  • Optison™
  • Passive cavitation detection
  • Ultrasound

ASJC Scopus subject areas

  • Biophysics
  • Radiological and Ultrasound Technology
  • Acoustics and Ultrasonics

Fingerprint

Dive into the research topics of 'A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations'. Together they form a unique fingerprint.

Cite this